IL320219A - מעכבים - Google Patents

מעכבים

Info

Publication number
IL320219A
IL320219A IL320219A IL32021925A IL320219A IL 320219 A IL320219 A IL 320219A IL 320219 A IL320219 A IL 320219A IL 32021925 A IL32021925 A IL 32021925A IL 320219 A IL320219 A IL 320219A
Authority
IL
Israel
Prior art keywords
inhibitors
Prior art date
Application number
IL320219A
Other languages
English (en)
Inventor
Carola Wenander
Anneline Nansen
Original Assignee
Zealand Pharma As
Carola Wenander
Anneline Nansen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As, Carola Wenander, Anneline Nansen filed Critical Zealand Pharma As
Publication of IL320219A publication Critical patent/IL320219A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Insects & Arthropods (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
IL320219A 2022-10-18 2023-10-18 מעכבים IL320219A (he)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22202304 2022-10-18
EP23184483 2023-07-10
PCT/EP2023/079008 WO2024083919A1 (en) 2022-10-18 2023-10-18 Inhibitors

Publications (1)

Publication Number Publication Date
IL320219A true IL320219A (he) 2025-06-01

Family

ID=88558319

Family Applications (1)

Application Number Title Priority Date Filing Date
IL320219A IL320219A (he) 2022-10-18 2023-10-18 מעכבים

Country Status (10)

Country Link
EP (1) EP4604984A1 (he)
JP (1) JP2025534884A (he)
KR (1) KR20250089536A (he)
CN (1) CN120265307A (he)
AU (1) AU2023362029A1 (he)
CA (1) CA3267935A1 (he)
CL (1) CL2025001051A1 (he)
IL (1) IL320219A (he)
MX (1) MX2025004515A (he)
WO (1) WO2024083919A1 (he)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723268B2 (en) 1996-09-09 2000-08-24 Zealand Pharma A/S Improved solid-phase peptide synthesis and agent for use in such synthesis
GB0414272D0 (en) 2004-06-25 2004-07-28 Cellpep Sa OsK1 derivatives
AU2005294124B2 (en) 2004-10-07 2012-02-23 Bachem Biosciences, Inc. Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
US8429751B2 (en) 2009-03-13 2013-04-23 Trustwave Holdings, Inc. Method and apparatus for phishing and leeching vulnerability detection
LT2948559T (lt) 2013-01-25 2018-06-25 Janssen Biotech, Inc. Kv1.3 antagonistai ir jų panaudojimo būdai
US9937230B2 (en) 2013-07-22 2018-04-10 Kineta One, Llc Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
WO2016112208A2 (en) 2015-01-09 2016-07-14 Kineta One, Llp Topical applications of kv1.3 channel blocking peptides to treat skin inflammation
CA3155089A1 (en) * 2019-09-20 2021-03-25 Zealand Pharma A/S Kv1.3 blockers
US20240182531A1 (en) * 2021-03-23 2024-06-06 Zealand Pharma A/S KV1.3 Blockers

Also Published As

Publication number Publication date
CL2025001051A1 (es) 2025-08-01
MX2025004515A (es) 2025-05-02
CA3267935A1 (en) 2024-04-25
JP2025534884A (ja) 2025-10-20
AU2023362029A1 (en) 2025-04-03
WO2024083919A1 (en) 2024-04-25
EP4604984A1 (en) 2025-08-27
KR20250089536A (ko) 2025-06-18
CN120265307A (zh) 2025-07-04

Similar Documents

Publication Publication Date Title
EP4262807A4 (en) Azachinazoline pan-KRAS inhibitors
IL325340A (he) מעכבי kras
IL314049A (he) מעכבי parp7
IL326137A (he) מעכבי pi3k
GB202008201D0 (en) Inhibitor compounds
EP4404927A4 (en) METHANOGEN INHIBITORS
GB202004960D0 (en) Inhibitor compounds
GB202110373D0 (en) Inhibitor compounds
GB202300881D0 (en) Inhibitor compounds
SMT202500406T1 (it) Inibitori del tead
GB202307924D0 (en) Inhibitor compounds
IL316378A (he) מעכבי פיאי3קיאי (pi3kα)
IL320219A (he) מעכבים
EP4263533C0 (en) Erap inhibitors
IL325676A (he) מעכבים של kat6
GB202505800D0 (en) Inhibitors
GB202416727D0 (en) RAB27 inhibitors
GB202416258D0 (en) Inhibitors
IL313756A (he) מעכבים של מכלול ססטרין-mapk
GB202319181D0 (en) Nora Inhibitors
GB202117224D0 (en) Inhibitor compounds
GB202112240D0 (en) Inhibitor compounds
GB202306601D0 (en) Inhibitor compounds
IL326489A (he) מעכבי 17 בתא- hsd1בלתי הפיכים
GB202215245D0 (en) Inhibitor compounds